- The report contains detailed information about Oxford BioMedica PLC that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for Oxford BioMedica PLC. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
- The Oxford BioMedica PLC financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
- In the part that describes Oxford BioMedica PLC competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Oxford BioMedica PLC business.
About Oxford BioMedica PLC
Oxford BioMedica plc, a biopharmaceutical company, specializes in the development of gene-based therapeutics with a focus on the areas of oncology and neurotherapy. The company principally operates in the United Kingdom, North America, and in Europe.
The company also operates in-house clinical, regulatory, and manufacturing know-how. The companys development pipelines include two anti-cancer products in phase II clinical trials; two neurotherapy products in improved preclinical development for Parkinsons disease and retinopathy; and three preclinical neurotherapy products.
The company operates a wholly owned subsidiary BioMedica, Inc. in San Diego, California. The company has collaborations with Wyeth, Intervet, Amersham, Viragen, MolMed, and Kiadis, and has licensed its Lenti Vector technology to various companies, including Merck & Co. and Biogen Idec.
TroVax: TroVax is Oxford BioMedicas major cancer immunotherapy product. It is a cancer vaccine in clinical development with potential application in most solid tumour types.
MetXia: MetXia is Oxford BioMedicas major gene-based cancer therapeutic. The product is based on an engineered retrovirus vector expressing the human cytochrome P450 gene, CYP2B6. MetXia converts a tumour into a drug factory, enabling increased local production of the anti-tumour, cytotoxic derivative of the prodrug cyclophosphamide (CPA). MetXia is useful in the treatment of all solid tumours and their metastases.
ProSavin: ProSavin is Oxford BioMedicas therapeutic for the treatment of late stage Parkinson's disease. It delivers genes for dopamine synthesis to the brain via the companys proprietary LentiVector technology.
RetinoStat: Age-related macular degeneration (AMD) and proliferative diabetic retinopathy (PDR) are diseases caused by inappropriate, unregulated and aberrant blood vessel growth (angiogenesis) as a consequence of angiogenic factor (VEGF) expression induced under hypoxic conditions in the retina. RetinoStat is Oxford BioMedicas gene-based product that is designed to halt this process. The product comprises a LentiVector system expressing an angiostatic gene under the control of Oxford BioMedicas proprietary hypoxia response element (HRE) which promotes gene expression under low oxygen conditions. The Company has an exclusive license to the angiostatics, endostatin and angiostatin, for the treatment of vision-loss via localised gene delivery.
MoNuDin: MoNuDin is used for the treatment of motor neuron disease, using gene-directed expression of therapeutic molecules. The product is a LentiVector system carrying a neuroprotective gene. Oxford BioMedica has collaboration in place with the ALS association, a US motor neuron disease charity. Commercial partners are sought to co-develop and market the product.
Innurex: Oxford BioMedicas LentiVector technology is a versatile system available for delivering genes to cells of the central and peripheral nervous system. Innurex is a product that uses this technology to deliver a gene that induces neurons to produce neurite outgrowths.
Repoxygen: Repoxygen is a gene-based therapeutic for the treatment of anaemia. The product concept is to deliver the Epo gene to the muscle cells in a vector configuration that brings the gene under the control of an oxygen-sensitive gene switch.
Requinate: Requinate is a gene-based therapeutic for the treatment of haemophilia. Requinate has the potential to cure this disease with infrequent administration via insertion of the correct gene into long-lived cells in the recipient.
ImmStat: ImmStat is a gene-based therapeutic for HIV infection and AIDS, based on potent HIV-based vectors designed to protect the immune system of HIV+ patients.
The company and drugmaker Sanofi-Aventis announced have entered into an agreement to jointly develop and market the cancer treatment TroVax.
Oxford BioMedica plc has entered into a research and collaboration agreement with the Foundation Fighting Blindness, Inc. to develop a portfolio of gene therapy products for treating eye diseases.
Oxford BioMedica has a licensing program for its LentiVector technology. The agreements allow licensees to use the companys proprietary gene delivery system for research activities. Oxford BioMedica has provided licenses to Merck & Co and Biogen Idec.
Oxford BioMedica plc was founded in 1995.
The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.
1. OXFORD BIOMEDICA PLC COMPANY PROFILE
1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History
2. OXFORD BIOMEDICA PLC BUSINESS OVERVIEW
2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units
3. OXFORD BIOMEDICA PLC SWOT ANALYSIS
4. OXFORD BIOMEDICA PLC FINANCIAL ANALYSIS
4.1. Financial Statements
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot
5. OXFORD BIOMEDICA PLC COMPETITORS AND INDUSTRY ANALYSIS
5.1. Oxford BioMedica PLC Direct Competitors
5.2. Comparison of Oxford BioMedica PLC and Direct Competitors Financial Ratios
5.3. Comparison of Oxford BioMedica PLC and Direct Competitors Stock Charts
5.4. Oxford BioMedica PLC Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
5.4.2. Oxford BioMedica PLC Industry Position Analysis
6. OXFORD BIOMEDICA PLC NEWS & EVENTS
6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events
7. OXFORD BIOMEDICA PLC EXPERTS REVIEW1
7.1. Experts Opinion
7.2. Experts Estimates
8. OXFORD BIOMEDICA PLC ENHANCED SWOT ANALYSIS2
9. UK PESTEL ANALYSIS2
9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors
10. OXFORD BIOMEDICA PLC IFE, EFE, IE MATRICES2
10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix
11. OXFORD BIOMEDICA PLC PORTER FIVE FORCES ANALYSIS2
12. OXFORD BIOMEDICA PLC VRIO ANALYSIS2
APPENDIX: RATIO DEFINITIONS
LIST OF TABLES
Oxford BioMedica PLC Key Facts
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Oxford BioMedica PLC Key Executives
Key Executives Biographies1
Key Executives Compensations1
Oxford BioMedica PLC Major Shareholders
Oxford BioMedica PLC History
Oxford BioMedica PLC Products
Revenues by Segment
Revenues by Region
Oxford BioMedica PLC Offices and Representations
Oxford BioMedica PLC SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Oxford BioMedica PLC Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Oxford BioMedica PLC Capital Market Snapshot
Oxford BioMedica PLC Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Oxford BioMedica PLC Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Oxford BioMedica PLC Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Revenue Estimates Trend1
Earnings Estimates Trend1
LIST OF FIGURES
Oxford BioMedica PLC Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Oxford BioMedica PLC 1-year Stock Charts
Oxford BioMedica PLC 5-year Stock Charts
Oxford BioMedica PLC vs. Main Indexes 1-year Stock Chart
Oxford BioMedica PLC vs. Direct Competitors 1-year Stock Charts
Oxford BioMedica PLC Article Density Chart
1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.
Enhanced SWOT Analysis
Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:
- How to use the strengths to take advantage of the opportunities?
- How to use the strengths to reduce likelihood and impact of the threats?
- How to overcome the weaknesses that obstruct taking advantage of the opportunities?
- How to overcome the weaknesses that can make the threats a reality?
Upon answering these questions a company can develop a project plan to improve its business performance.
PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.
Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.
Key Factors Examined by PESTEL Analysis:
- Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
- Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
- Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
- Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
- Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
- Legal – What laws and legislation will exert influence on the style the business is carried out?
IFE, EFE, IE Matrices
The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.
The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.
The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.
Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.
Porter Five Forces Analysis
The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:
- What composes a threat of substitute products and services?
- Is there a threat of new competitors entering the market?
- What is the intensity of competitive rivalry?
- How big is the bargaining power of buyers?
- How significant is the bargaining power of suppliers?
VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:
- Tangible resources
- Intangible resources
- Innovation and Creativity
- Organizational capabilities
The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:
- Costly to imitate?
- Organized properly?